Global Tularemia Treatment Market -2023-2030

Overview

The global tularemia treatment market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. Francisella tularensis, a gram-negative, aerobic, pleomorphic bacillus, causes tularemia, an acute, granulomatous, febrile, infectious zoonosis. One of the most contagious bacterial species is F. tularensis.

Up to 20% of tularemia patients experience a rash that might start as macular, blotchy, or maculopapular before developing into pustular in nature. Erythema multiforme and erythema nodosum are uncommon.

Government investments and research, particularly in developing economies, will continue to drive utilization of advanced products for novel treatments such as doxycycline or streptomycin for glandular tularemia and boost the global tularemia treatment market.

Market Dynamics: Drivers & Restraints

Increasing collaborations along with drug launches

Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for tularemia treatment owing to the rising research. Various collaborations, acquisitions and license agreement with technological advancements among different countries will be a crucial factor driving the growth of the market.

On February 17, 2022, researchers at Defence Science and Technology Laboratory (Dstl) have demonstrated that an antibiotic developed for the treatment of urinary tract infections is effective at treating a wide range of diseases, including plague and melioidosis. This work was done in collaboration with industry, academia, along with the Defence Threat Reduction Agency (DTRA). The antibiotic finafloxacin is being manufactured by MerLion Pharmaceuticals to treat urinary tract infections, but when compared to comparator drugs, its distinct mode of action has improved activity. In mouse infection models, finafloxacin effectively treats inhalational tularemia and plague.

Additionally, on June 25, 2021, through its American subsidiary, Hikma Pharmaceuticals USA Inc., the worldwide pharmaceutical business Hikma Pharmaceuticals PLC has introduced Doxycycline Injection, USP, 100mg, in the US. An antibiotic called doxycycline injection is used for the treatment of infections that are definitely or highly believed to be brought on by bacteria that are sensitive.

Furthermore, the rising utilization of novel medicines and solutions for tularemia treatment. Rising glandular tularemia cases and increasing utilization of several drugs along with research for innovative product development will be a major factor driving the growth of the tularemia treatment market.

Side effects associated with the drugs

One in ten persons experience these doxycycline side effects often. Headaches, feeling ill (vomiting), nausea, and sun sensitivity are examples of side effects. Serious side effects can indicate blood issues and include bleeding or bruises that cannot be explained, including nosebleeds, a sore throat, a fever, and feeling weary or generally ill.

Diarrhea that is bloody or mucus-filled, along with buzzing or ringing in the ears, and possibly stomach cramps. Swallowing difficulties or pain, throat discomfort, acid reflux, a decrease in appetite, or chest pain that worsens while eating.

Segment Analysis

The global tularemia treatment market is segmented based on disease type, drugs, route of administration, distribution channel and region.

Ulceroglandular tularemia disease type segment accounted for approximately 48% of market share

By the bacteria Francisella tularensis, which is prevalent throughout the northern hemisphere, tularemia, a rare zoonotic infection, is brought on. Through inoculation from the bites of arthropod vectors like ticks or stag flies, or by handling contaminated tissue from naturally occurring animal reservoirs like rabbits or small rodents, the ulceroglandular type of illness is spread.

Other types of exposure to polluted fluid or aerosol may cause systemic "typhoidal" disease, oropharyngeal disease, oculoglandular disease, or pneumonic disease. Intravenous aminoglycosides were once the standard of care, but recent research has shown that milder cases can be successfully treated with oral antibiotics such ciprofloxacin or tetracycline. With the rising population and growing geographical reach of its tick vectors, it is possible to expect an increase in the incidence of tularemia globally.

According to Illinois Department of Public Health, every year, the United States reports between 100 and 200 instances. Tularemia can result in six different disease types, although up to 80% of cases are "ulceroglandular" (characterized by skin ulcers and enlarged lymph nodes) and are brought on by close contact involving infected animals.

Geographical Penetration

North America accounted for around 39% of market share in 2022

Due to the rising need for tularemia treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for tularemia treatment.

Increasing expenditure on healthcare, advancement of technologies and different treatment products for different tularemia disease types, along with increase in biopharmaceutical or biotechnology business establishment across the region are also contributing to the growth of tularemia treatment market share of this region. The market in this area is growing as people become more aware of various novel treatments. The aforementioned elements attest to North America's hegemonic position in the world.

North America continues to be a key player in the global tularemia treatment market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for antibiotics such as aminoglycosides in the United States which have been proactive in executing several initiatives or treatment, stimulating these drugs demand.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global tularemia treatment market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of fluoroquinolones or tetracyclines, was significantly impacted. The widespread lockdowns and restrictions imposed by the pandemic, which began in early 2020, had an effect on a number of initiatives all around the world.

Major medical and biotechnology industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for tularemia treatment. Now several research studies have been initiated and companies have again started trial for their products efficiency. Overall, the impact of the pandemic on the global tularemia treatment market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for novel treatments.

Key Developments

• On August 14, 2023, for Delayed-Release Doxycycline Hyclate Tablets USP, 50 mg, 60 mg, 80 mg, 100 mg, 150 mg, and 200 mg, an abbreviated novel drug application has been approved by the US Food and Drug Administration (US FDA) for marketing as a generic alternative to Doryx MPC Delayed-Release Tablets and Doryx Delayed-Release Tablets of Mayne Pharma International Pty. Ltd.
• On January 4, 2022, the US Food & Drug Administration (USFDA) has given its final approval to Alembic Pharmaceuticals Limited's Abbreviated Novel Drug Application (ANDA) for Delayed-Release, Doxycycline Hyclate Tablets USP, 100 mg, 150 mg, or 200 mg. The ANDA that has been approved is therapeutically similar to Mayne Pharma International Pty. Ltd.'s Doryx Tablets, 100 mg, 150 mg, or 200 mg.

Competitive Landscape

The major global players in the market include: Pfizer Inc., Merck KGaA, Fujian Fukang Pharmaceutical Co., Ltd, Hikma Pharmaceuticals PLC, Cepham Life Sciences, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Midas Pharma GmbH, Camber Pharmaceuticals, Inc. and FUJIFILM Wako Pure Chemical Corporation.

Why Purchase the Report?

• To visualize the global tularemia treatment market segmentation based on disease type, drugs, route of administration, distribution channel and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of tularemia treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global tularemia treatment market report would provide approximately 69 tables, 70 figures and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies